Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report)’s stock price fell 11.1% on Tuesday after Leerink Partners lowered their price target on the stock from $9.00 to $8.00. Leerink Partners currently has a market perform rating on the stock. Recursion Pharmaceuticals traded as low as $6.22 and last traded at $6.47. 4,228,886 shares changed hands during mid-day trading, a decline of 29% from the average session volume of 5,934,939 shares. The stock had previously closed at $7.28.
Several other research analysts also recently commented on RXRX. Needham & Company LLC decreased their price objective on Recursion Pharmaceuticals from $17.00 to $16.00 and set a “buy” rating on the stock in a report on Friday, August 9th. KeyCorp decreased their price target on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Finally, Jefferies Financial Group lowered their price objective on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Tuesday. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, Recursion Pharmaceuticals presently has an average rating of “Hold” and an average target price of $10.40.
Insider Buying and Selling at Recursion Pharmaceuticals
In other news, COO Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $7.56, for a total value of $45,360.00. Following the sale, the chief operating officer now directly owns 521,138 shares in the company, valued at approximately $3,939,803.28. The sale was disclosed in a filing with the SEC, which is available through this link. In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $9.51, for a total transaction of $108,860.97. Following the sale, the director now directly owns 7,177,116 shares of the company’s stock, valued at approximately $68,254,373.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $7.56, for a total value of $45,360.00. Following the completion of the transaction, the chief operating officer now owns 521,138 shares of the company’s stock, valued at approximately $3,939,803.28. The disclosure for this sale can be found here. Insiders sold 261,682 shares of company stock valued at $2,036,272 in the last 90 days. Insiders own 15.75% of the company’s stock.
Hedge Funds Weigh In On Recursion Pharmaceuticals
A number of institutional investors have recently added to or reduced their stakes in RXRX. Benjamin F. Edwards & Company Inc. purchased a new stake in shares of Recursion Pharmaceuticals in the first quarter worth $26,000. National Bank of Canada FI increased its stake in shares of Recursion Pharmaceuticals by 90.9% in the fourth quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock worth $31,000 after purchasing an additional 1,500 shares in the last quarter. First Horizon Advisors Inc. bought a new stake in Recursion Pharmaceuticals during the fourth quarter valued at about $47,000. GAMMA Investing LLC raised its stake in Recursion Pharmaceuticals by 1,588.4% during the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock valued at $48,000 after purchasing an additional 6,036 shares during the period. Finally, Amalgamated Bank lifted its holdings in Recursion Pharmaceuticals by 52.4% in the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after purchasing an additional 2,459 shares in the last quarter. Institutional investors own 89.06% of the company’s stock.
Recursion Pharmaceuticals Stock Down 16.6 %
The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04. The company has a 50 day simple moving average of $7.50 and a two-hundred day simple moving average of $8.99. The firm has a market capitalization of $1.44 billion, a P/E ratio of -3.85 and a beta of 0.83.
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). The company had revenue of $14.42 million during the quarter, compared to the consensus estimate of $11.96 million. Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The business’s revenue was up 30.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.38) earnings per share. On average, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.6 EPS for the current fiscal year.
Recursion Pharmaceuticals Company Profile
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.